Regenerative medicine

Our

Mission

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.

The platforms can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over $37 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Our

HISTORY

2009

FANTOM 5 LAUNCH

RIKEN scientists launch an international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.

2014

MOGRIFY VALIDATION

Collaboration with Jose Polo to test cell conversions begins and three conversions are validated in just several months.

2016

NATURE GENETICS

Mogrify V1 platform and cell conversions results published in Nature Genetics journal featuring on the front page.

2018/2019

GROWTH PHASE

$3.7M seed capital raised, Dr. Darrin M. Disley, OBE appointed as CEO, and Dr. Jane Osbourn, OBE appointed as Chair, hired 40 scientists and raised an additional $16 million in the initial close of Series A funding.

2020

CELL SYSTEMS

epiMOGRIFY cell identity platform and validation published in Cell Systems journal.

2011

MOGRIFY DEVELOPMENT

Julian Gough and Owen Rackham begin the V1 platform development using the unpublished FANTOM 5 consortium data.

2015

FOUNDATION PATENT

Julian Gough, Owen Rackham, Jose Polo file a patent application for the V1 platform and over 30 direct cell conversions.

2016/2018

INCORPORATION

Mogrify is incorporated in February 2016 by the three academic Co-founders: J. Gough, O. Rackham & J. Polo with pre-seed and grant funding to begin the industrial development and application of the V1 platform.

2020

PROOF OF CONCEPT

First milestone & royalty-bearing deals executed. Appointed Dr. Lorenz Mayr, Prof. Graziella Pellegrini, Prof. Giulio Cossu and Prof. Christine Mummery to the Scientific Advisory Board (SAB). Progression of internal programs to in vitro and in vivo proof-of-concept stage.

2021

ROAD TO IND

Second close of $17 million brings total raised in Series A to $33 million supporting the advancement of immuno-oncology and ophthalmology programs through to IND-enabling studies.

Our

Awards

Cambridge Business Awards 2020 - Winner - Mogrify

Business of the Year 2020

The ‘Innovation in Business’ and ‘Business of the Year‘ Awards recognize the potential of Mogrify’s technology to accelerate the development of regenerative cell and in vivo reprogramming therapies.

BusinessWeekly-2019-Winner_Mogrify

Life Science Innovation Award 2020

The ‘Life Science Innovation‘ Award recognizes the Company’s efforts in applying its direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare.

Scrip-Awards-2019-Winner_Mogrify

MSD’s Innovation
Award 2019

The Innovation Award at Scrip recognizes the significant potential the Company’s direct cellular conversion technology has to disrupt the future development of new medicines.

BusinessWeekly-2019-Winner_Mogrify

Disruptive Technology Award 2019

The ‘Disruptive Technology’ category at the Business Weekly Awards, recognizes the Company’s novel bioinformatic platform, which is built upon a decade of world-class multidisciplinary science.

LSX-Awards-2019-Winner_Mogrify

Seed Stage Finance Raise of the Year 2019

Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry.

CambridgeIndependant-Awards-2019-Winner_Mogrify

Named ‘The One to Watch’ 2019

Recognizing the potential of the Company’s proprietary direct cellular conversion technology, enabling any mature adult cell to be transformed into any other, without going through a pluripotent stem cell-state.